Adavnces in genomic and proteomic technologies have made the availability of biospecimens andcorresponding data critical to understanding the molecular basis of human diseases such as stroke.Accordingly, the goal of the Biospecimen Procurement Core is to collect, process, store, and distributebiospecimens from patients in the context of both this proposal's clinical trials and during the routinetreatment of patients at this medicial center.
The first aim of this core is to support the collection andprocessing of serum, plasma, CSF, and genomic DMA from patients (approximately 50 per year) enrolled instudies described in projects 1-3. Samples will be collected upon study entry and over multiple time pointsas permissable, to create a set of biospecimens that can be analyzed over time and correlated with clinicalprogression. When avaialble and appropriate, the core will also provide support to collect tissue specimensfrom patients.
The second aim of this core is to create a more expansive biospecimen resource consisting ofsingle time-point serum, plasma, and genomic DMA from all stroke patients (-800 per year) seen at thisinstitution.
The third aim of this core is to create an inventory of available biospecimen resources and deidentifieddata that can be accessed by authorized intramural and extramural SPOTRIAS investigators, forthe purposes of sharing this biospecimen resource to promote novel clinical correlative studies in strokeprevention and treatment. To accomplish these goals, this core will capitalize on the extensive infrastructurethat has already been developed for biospecimen management at our institution. Patient recruitment andconsenting will be coordinated with Patient Core B. Biospecimens and associated data mangement will becoordinated with Biostatistics Core D and de-identified using a well-established honest broker mechanism.Specimen processing, storage, and quality assurance will utilize standardized operating procedures thathave been in place in our institutional tissue bank for the past seven years. Generation and bioinformaticmanagement of genomic polymorphism (SNP) data (although not specifically proposed in any of the currentprojects) will also be supported by the institution's GeneChip facility. Finally, biospecimen datamanagement and data publishing will take advantage of efforts at our institution to develop an enterpriseclass,web-accessible biospecimen database (caTISSUE Core).
Showing the most recent 10 out of 44 publications
